Table 1 Baseline characteristics of HCV patients receiving RDV/SOF. (N = 580).
Overall (N = 580) | Noncirrhosis (n = 350) | Cirrhosis (n = 230) | |
|---|---|---|---|
Sex | |||
Female | 127 (21.9) | 77 (22.0) | 50 (21.7) |
Male | 453 (78.1) | 273 (78.0) | 180 (78.3) |
Age group (years) | 46.8 ± 10.5 | 44.3 ± 10.5 | 50.8 ± 9.3 |
< 45 | 239 (41.2) | 179 (51.1) | 60 (26.1) |
≥ 45 | 341 (58.8) | 171 (48.9) | 170 (73.9) |
Country of treatment | |||
Malaysia | 381 (65.7) | 178 (50.9) | 203 (88.3) |
Thailand | 199 (34.3) | 172 (49.1) | 27 (11.7) |
HCV genotype | |||
1 | 230 (39.7) | 162 (46.3) | 68 (29.6) |
2 | 3 (0.5) | 3 (0.9) | 0 |
3 | 290 (50.0) | 135 (38.6) | 155 (67.4) |
6 | 57 (9.8) | 50 (14.3) | 7 (3.0) |
Baseline HCV RNA (IU/mL) | |||
< 800,000 | 184 (31.7) | 104 (29.7) | 80 (34.8) |
≥ 800,000 | 396 (68.3) | 246 (70.3) | 150 (65.2) |
IL-28B genotype | |||
CC | 447 (77.1) | 266 (76.0) | 181 (78.7) |
CT + TT | 133 (22.9) | 84 (24.0) | 49 (21.3) |
HIV coinfection | |||
No | 396 (68.3) | 208 (59.4) | 188 (81.7) |
Yes | 184 (31.7) | 142 (40.6) | 42 (18.3) |
Previous interferon treatment exposure | |||
Treatment-experienced | 117 (20.2) | 70 (20.0) | 47 (20.4) |
Treatment-naïve | 463 (79.8) | 280 (80.0) | 183 (79.6) |
Injection drug use | |||
No | 310 (53.4) | 187 (53.4) | 123 (53.5) |
Yes | 270 (46.6) | 163 (46.6) | 107 (46.5) |
Liver stiffness (kPa) | 13.7 ± 10.6 | 7.3 ± 2.4 | 23.5 ± 10.8 |
Use of concomitant medications | |||
No | 54 (9.3) | 41 (11.7) | 13 (5.7) |
Yes | 526 (90.7) | 309 (88.3) | 217 (94.3) |
Comorbidities | |||
No | 481 (82.9) | 302 (86.3) | 179 (77.8) |
Yes | 99 (17.1) | 48 (13.7) | 51 (22.2) |
Common comorbidities | |||
Diabetes mellitus | 48 (8.3) | 19 (5.4) | 29 (12.6) |
Obesity | 29 (5.0) | 9 (2.6) | 20 (8.7) |
NAFLD | 30 (5.2) | 17 (4.9) | 13 (5.7) |
